Incorporation of the Anti-JC Virus Antibody Assay and Oral DMAs, Including Aubagio, are Top of Mind Recent Changes in the Management of Multiple Sclerosis Patients for Surveyed U.S. Neurologists

Incorporation of the Anti-JC Virus Antibody Assay and Oral DMAs, Including Aubagio, are Top of Mind Recent Changes in the Management of Multiple Sclerosis Patients for Surveyed U.S. Neurologists

Data in the recently published TreatmentTrends: Multiple Sclerosis Q1 2013 report also suggest that, despite Biogen Idec‘s recent application requesting expansion of Tysabri‘s label to include first-line use among seronegative patients with relapsing MS, serostatus may not have a strong impact on first-line brand preference, given that Teva‘s

Responder

Por favor, inicia sesión con uno de estos métodos para publicar tu comentario:

Logo de WordPress.com

Estás comentando usando tu cuenta de WordPress.com. Cerrar sesión / Cambiar )

Imagen de Twitter

Estás comentando usando tu cuenta de Twitter. Cerrar sesión / Cambiar )

Foto de Facebook

Estás comentando usando tu cuenta de Facebook. Cerrar sesión / Cambiar )

Google+ photo

Estás comentando usando tu cuenta de Google+. Cerrar sesión / Cambiar )

Conectando a %s